Three Companies with the Ingredients to Follow in the Footsteps of Advaxis (NASDAQ: ADXS)
willing to support the Company's plans to progress PRP into clinical trials," said James Nathanielsz, Propanc's Chief Executive Officer, "Whilst I am grateful for the working capital which has been put to good use for the Company, the Board is now focusing its attention on reducing overall debt, increasing cash reserves and investing additional funds into our research and development activities."
but to me it is a pure sell, expect dilution and riverse spilt 10000 to 1, co has lot of debt , it will take years to clear the debt,
no one can stop.
this is nothing, investors do not have any idea about the company and their product. undervalue stocks, In my opinion it is a pure steal if you have 1 M shares.
day for market sell off , ley say -500 down